Insiders · CARM

Michael Klichinsky

Chief Scientific Officer at Carisma Therapeutics Inc. (CARM) since March 2023

Michael Klichinsky has filed 8 insider reports with the SEC since March 2023, as chief Scientific Officer at Carisma Therapeutics Inc. (CARM). Michael Klichinsky made no open-market purchases or sales in the last 12 months. In the latest filing, on October 8, 2025, Michael Klichinsky sold 56,982 shares of Carisma Therapeutics Inc. (CARM) for $14.5K at an average of $0.25.

Filings
8
Companies
1
Bought on market
None
Sold on market
$139K

Companies where Michael Klichinsky is an insider

CompanyRoleShares heldBoughtSoldAvg buyPrice nowLast filing
Carisma Therapeutics Inc. logo
CARM
Carisma Therapeutics Inc.
Chief Scientific Officersince March 20230$139KOct 8, 2025

Shares held: common shares owned directly after the latest filing that states it. Avg buy: open-market purchase dollars divided by shares bought, every filing on record.

Every filing

Compare Michael Klichinsky with

Other insiders at the same companies

Questions about Michael Klichinsky

What is Michael Klichinsky's role at Carisma Therapeutics Inc.?
Michael Klichinsky reports to the SEC as chief Scientific Officer at Carisma Therapeutics Inc. (CARM), according to the latest filing on October 8, 2025.
Has Michael Klichinsky bought or sold stock recently?
The most recent open-market sale was on October 7, 2025: sold 56,982 shares of Carisma Therapeutics Inc. (CARM) for $14.5K at an average of $0.25.
How do I get alerts when Michael Klichinsky files?
Follow Michael Klichinsky on Quantisnow and you get an email, and a phone notification on Plus, within minutes of each new Form 4 or Form 5, and of each Form 144 notice of a planned sale.

From SEC Forms 3, 4, 5 and 144 filed by Michael Klichinsky (SEC CIK 0001967221). Totals count each trade once, skipping amendments whose original is on file, from Mar 10, 2023 on. View on SEC EDGAR · Get this as JSON